The following case-study demonstrates a 58% reduction in breast cancer costs alone through early intervention

Presumptions

• In a target population of 1,000 women 12.9% will develop Breast Cancer in their lifetime(1)
• With a 65% average compliance rate with breast cancer in the U.S. (2)​, you can expect to find 84 Cancers
• If only 84 employees have been screened, how do you address the 45 employees who have cancer, but have not been diagnosed?

Sample Female ​Population	12.9% Lifetime Risk of BC	65% Compliance  Rate Should find This many cancers	Remaining Undiagnosed ​(35%)
1000	129	84	45

Predicted Financial Benefit

• According to a 2022 study by BMC Health Services Research, the average cost of treating Stage 1 Breast cancer is $56,507; whereas the cost of treating a Stage-4 Breast Cancer is $133,100 (3)
• The late-stage cost of treating 45 employees with late-stage Breast Cancer is $5,989,500
• If caught early in the same 45 employees, the cost would only be $2,542,815

Treatment Cost  Stage 1	Treatment Cost  ​Stage 4	Cost of Treating 45 Women ​at Stage 1	Cost of Treating 45 Women ​at Stage 4	Achieved Savings
$56,507	$133,100	$2,542,815	$5,989,500	$3,446,685

​A Cost Avoidance of $3,446,685
For Breast Cancer Alone

Vertical Divider

Contact us to learn more

Our Process is Our Difference

---

StageZero provides advanced diagnostics that can not only identify cancer earlier among employees, but also identify the early warning signs that can lead to a future cancer diagnosis. This paired with a physician supervised intervention program run by experienced oncologists can reduce costs for your organization dramatically.

Our Programs Enhance Your Benefits 

---

ARISTOTLE®
Adressing Today's Cancer Earlier

Did you know 50% of Cancers are still found in the late stages when outcomes are poor and costs are high(5)?

Aristotle® is a new blood test that can detect the molecular signatures of multiple cancers from a single sample of blood to help you find cancer earlier and start treatment when it can dramatically improve patient outcomes. Aristotle can discretely detect each cancer signature with high sensitivity and specificity.(4) Today Aristotle can detect 9 specific cancers: 
Ovarian, Breast, Endometrial, Cervical, Bladder, Prostate, Colorectal, Liver and Stomach. 

​Our underlying mRNA technology, The Sentinel Principle, has been validated in more than ​9,000 patients and used by more than 100,000 patients in North America. (4) 

Learn More

​AVRT™
Addressing Tomorrow's Cancer Today

Did you know 40% of the most common cancers are preventable through modifiable risk factors(6)?

AVRT (pronounced "avert") identifies early risk factors that may lead to cancer and provides actionable information to help people adopt lifestyle modifications to help reduce their risk. ​

​We assess the inflammatory and metabolic pathways that have been demonstrated to increase the risk of developing cancer and other chronic diseases.

Learn More

LATEST NEWS 

Results from METRICs Study Informs Expansion of StageZero's New Care Oncology Protocol

StageZero Life Sciences Announces Change of Date of Special Meeting of Shareholders; Will Combine with AGM in Q2 2023
2/2/23

​Our Mission

Today the field of cancer research and discovery is focused on the "Moonshot" - a cure for cancer. But at StageZero Life Sciences we believe in "groundshots" too by doing whatever we can to help improve outcomes through cancer prevention, earlier cancer detection and adjunctive cancer therapy to improve cancer outcomes.

​Our Laboratory

StageZero Life Sciences U.S. Headquarters is based in Richmond, VA. Our laboratory in Richmond is registered and certified according to the Clinical Laboratory Improvement Amendment (CLIA) for high complexity laboratory testing through the Centers of Medicare and Medicaid Services (CMS). In addition, the lab is accredited through the U.S. College of American Pathologists (CAP). These certifications demonstrate our highest commitment to excellence in laboratory test processing and our passion for patient care. 

​

References
​1. https://www.cancer.gov/types/breast/risk-fact-sheet 
2.https://www.cdc.gov/nchs/hus/topics/mammography.html
3. McGarvey, N., Gitlin, M., Fadli, E. et al. Increased healthcare costs by later stage cancer diagnosis. BMC Health Serv Res 22, 1155 (2022). https://doi.org/10.1186/s12913-022-08457-6 American
4. Aristotle: A single blood test for pan-cancer screening. Dempsey AA, Chao S, Stamatiou D, Pilcz T, Ying J, Burakoff R. Journal of Clinical Oncology 2020; 38:15_suppl e15037
5. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021 Jan;71(1):7-33.
6.GBD 2019 Cancer Risk Factors Collaborators. The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022 Aug 20;400(10352):563-591. doi: 10.1016/S0140-6736(22)01438-6. PMID: 35988567. 

​Headline on catastrophic cancer claims: 2022 Sun Life Stop-Loss Research Report: High-cost Claims and Injectable Drug Trends Analysis.
​
​Aristotle™ was developed, and its performance characteristics determined by Stage Zero Life Sciences, Inc.; they have not been cleared or approved by the US Food and Drug Administration.